Opinion|Videos|April 28, 2025
The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.
Advertisement
Video content above is prompted by the following:
- Previously, I mentioned the benefits of Lp(a) testing, even in the absence of targeted Lp(a)-lowering therapies. Let’s explore that further. How might Lp(a) testing improve overall cardiovascular risk assessment?
- How, if at all, might Lp(a) measurement influence the management of other risk factors?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
5